Yezi Zhu1, Adam Sharp2, Courtney M Anderson3, John L Silberstein1, Maritza Taylor1, Changxue Lu1, Pei Zhao1, Angelo M De Marzo4, Emmanuel S Antonarakis5, Mindy Wang3, Xingyong Wu3, Yuling Luo3, Nan Su3, Daniel Nava Rodrigues6, Ines Figueiredo6, Jonathan Welti6, Emily Park3, Xiao-Jun Ma3, Ilsa Coleman7, Colm Morrissey8, Stephen R Plymate8, Peter S Nelson9, Johann S de Bono10, Jun Luo11. 1. Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 2. The Institute for Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK. 3. Advanced Cell Diagnostics, Newark, CA, USA. 4. Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 5. Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 6. The Institute for Cancer Research, London, UK. 7. Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 8. University of Washington, Seattle, WA, USA. 9. Fred Hutchinson Cancer Research Center, Seattle, WA, USA; University of Washington, Seattle, WA, USA. 10. The Institute for Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK. Electronic address: johann.de-bono@icr.ac.uk. 11. Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: jluo1@jhmi.edu.
Abstract
BACKGROUND: Androgen receptor splice variant 7 (AR-V7) has been implicated in resistance to abiraterone and enzalutamide treatment in men with metastatic castration-resistant prostate cancer (mCRPC). Tissue- or cell-based in situ detection of AR-V7, however, has been limited by lack of specificity. OBJECTIVE: To address current limitations in precision measurement of AR-V7 by developing a novel junction-specific AR-V7 RNA in situ hybridization (RISH) assay compatible with automated quantification. DESIGN, SETTING, AND PARTICIPANTS: We designed a RISH method to visualize single splice junctions in cells and tissue. Using the validated assay for junction-specific detection of the full-length AR (AR-FL) and AR-V7, we generated quantitative data, blinded to clinical data, for 63 prostate tumor biopsies. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We evaluated clinical correlates of AR-FL/AR-V7 measurements, including association with prostate-specific antigen progression-free survival (PSA-PFS) and clinical and radiographic progression-free survival (PFS), in a subset of patients starting treatment with abiraterone or enzalutamide following biopsy. RESULTS AND LIMITATIONS: Quantitative AR-FL/AR-V7 data were generated from 56 of the 63 (88.9%) biopsy specimens examined, of which 44 were mCRPC biopsies. Positive AR-V7 signals were detected in 34.1% (15/44) mCRPC specimens, all of which also co-expressed AR-FL. The median AR-V7/AR-FL ratio was 11.9% (range 2.7-30.3%). Positive detection of AR-V7 was correlated with indicators of high disease burden at baseline. Among the 25 CRPC biopsies collected before treatment with abiraterone or enzalutamide, positive AR-V7 detection, but not higher AR-FL, was significantly associated with shorter PSA-PFS (hazard ratio 2.789, 95% confidence interval 1.12-6.95; p=0.0081). CONCLUSIONS: We report for the first time a RISH method for highly specific and quantifiable detection of splice junctions, allowing further characterization of AR-V7 and its clinical significance. PATIENT SUMMARY: Higher AR-V7 levels detected and quantified using a novel method were associated with poorer response to abiraterone or enzalutamide in prostate cancer.
BACKGROUND:Androgen receptor splice variant 7 (AR-V7) has been implicated in resistance to abiraterone and enzalutamide treatment in men with metastatic castration-resistant prostate cancer (mCRPC). Tissue- or cell-based in situ detection of AR-V7, however, has been limited by lack of specificity. OBJECTIVE: To address current limitations in precision measurement of AR-V7 by developing a novel junction-specific AR-V7 RNA in situ hybridization (RISH) assay compatible with automated quantification. DESIGN, SETTING, AND PARTICIPANTS: We designed a RISH method to visualize single splice junctions in cells and tissue. Using the validated assay for junction-specific detection of the full-length AR (AR-FL) and AR-V7, we generated quantitative data, blinded to clinical data, for 63 prostate tumor biopsies. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We evaluated clinical correlates of AR-FL/AR-V7 measurements, including association with prostate-specific antigen progression-free survival (PSA-PFS) and clinical and radiographic progression-free survival (PFS), in a subset of patients starting treatment with abiraterone or enzalutamide following biopsy. RESULTS AND LIMITATIONS: Quantitative AR-FL/AR-V7 data were generated from 56 of the 63 (88.9%) biopsy specimens examined, of which 44 were mCRPC biopsies. Positive AR-V7 signals were detected in 34.1% (15/44) mCRPC specimens, all of which also co-expressed AR-FL. The median AR-V7/AR-FL ratio was 11.9% (range 2.7-30.3%). Positive detection of AR-V7 was correlated with indicators of high disease burden at baseline. Among the 25 CRPC biopsies collected before treatment with abiraterone or enzalutamide, positive AR-V7 detection, but not higher AR-FL, was significantly associated with shorter PSA-PFS (hazard ratio 2.789, 95% confidence interval 1.12-6.95; p=0.0081). CONCLUSIONS: We report for the first time a RISH method for highly specific and quantifiable detection of splice junctions, allowing further characterization of AR-V7 and its clinical significance. PATIENT SUMMARY: Higher AR-V7 levels detected and quantified using a novel method were associated with poorer response to abiraterone or enzalutamide in prostate cancer.
Authors: Emmanuel S Antonarakis; Changxue Lu; Brandon Luber; Hao Wang; Yan Chen; Mary Nakazawa; Rosa Nadal; Channing J Paller; Samuel R Denmeade; Michael A Carducci; Mario A Eisenberger; Jun Luo Journal: JAMA Oncol Date: 2015-08 Impact factor: 31.777
Authors: Emmanuel S Antonarakis; Changxue Lu; Hao Wang; Brandon Luber; Mary Nakazawa; Jeffrey C Roeser; Yan Chen; Tabrez A Mohammad; Yidong Chen; Helen L Fedor; Tamara L Lotan; Qizhi Zheng; Angelo M De Marzo; John T Isaacs; William B Isaacs; Rosa Nadal; Channing J Paller; Samuel R Denmeade; Michael A Carducci; Mario A Eisenberger; Jun Luo Journal: N Engl J Med Date: 2014-09-03 Impact factor: 91.245
Authors: Rong Hu; Thomas A Dunn; Shuanzeng Wei; Sumit Isharwal; Robert W Veltri; Elizabeth Humphreys; Misop Han; Alan W Partin; Robert L Vessella; William B Isaacs; G Steven Bova; Jun Luo Journal: Cancer Res Date: 2009-01-01 Impact factor: 12.701
Authors: Eleni Efstathiou; Mark Titus; Sijin Wen; Anh Hoang; Maria Karlou; Robynne Ashe; Shi Ming Tu; Ana Aparicio; Patricia Troncoso; James Mohler; Christopher J Logothetis Journal: Eur Urol Date: 2014-05-29 Impact factor: 20.096
Authors: Dan Robinson; Eliezer M Van Allen; Yi-Mi Wu; Nikolaus Schultz; Robert J Lonigro; Juan-Miguel Mosquera; Bruce Montgomery; Mary-Ellen Taplin; Colin C Pritchard; Gerhardt Attard; Himisha Beltran; Wassim Abida; Robert K Bradley; Jake Vinson; Xuhong Cao; Pankaj Vats; Lakshmi P Kunju; Maha Hussain; Felix Y Feng; Scott A Tomlins; Kathleen A Cooney; David C Smith; Christine Brennan; Javed Siddiqui; Rohit Mehra; Yu Chen; Dana E Rathkopf; Michael J Morris; Stephen B Solomon; Jeremy C Durack; Victor E Reuter; Anuradha Gopalan; Jianjiong Gao; Massimo Loda; Rosina T Lis; Michaela Bowden; Stephen P Balk; Glenn Gaviola; Carrie Sougnez; Manaswi Gupta; Evan Y Yu; Elahe A Mostaghel; Heather H Cheng; Hyojeong Mulcahy; Lawrence D True; Stephen R Plymate; Heidi Dvinge; Roberta Ferraldeschi; Penny Flohr; Susana Miranda; Zafeiris Zafeiriou; Nina Tunariu; Joaquin Mateo; Raquel Perez-Lopez; Francesca Demichelis; Brian D Robinson; Marc Schiffman; David M Nanus; Scott T Tagawa; Alexandros Sigaras; Kenneth W Eng; Olivier Elemento; Andrea Sboner; Elisabeth I Heath; Howard I Scher; Kenneth J Pienta; Philip Kantoff; Johann S de Bono; Mark A Rubin; Peter S Nelson; Levi A Garraway; Charles L Sawyers; Arul M Chinnaiyan Journal: Cell Date: 2015-05-21 Impact factor: 41.582
Authors: Emma Hörnberg; Erik Bovinder Ylitalo; Sead Crnalic; Henrik Antti; Pär Stattin; Anders Widmark; Anders Bergh; Pernilla Wikström Journal: PLoS One Date: 2011-04-28 Impact factor: 3.240
Authors: Michael C Haffner; Gunes Guner; Diana Taheri; George J Netto; Doreen N Palsgrove; Qizhi Zheng; Liana Benevides Guedes; Kunhwa Kim; Harrison Tsai; David M Esopi; Tamara L Lotan; Rajni Sharma; Alan K Meeker; Arul M Chinnaiyan; William G Nelson; Srinivasan Yegnasubramanian; Jun Luo; Rohit Mehra; Emmanuel S Antonarakis; Charles G Drake; Angelo M De Marzo Journal: Am J Pathol Date: 2018-03-22 Impact factor: 4.307
Authors: Jun Luo; Gerhardt Attard; Steven P Balk; Charlotte Bevan; Kerry Burnstein; Laura Cato; Artem Cherkasov; Johann S De Bono; Yan Dong; Allen C Gao; Martin Gleave; Hannelore Heemers; Mayuko Kanayama; Ralf Kittler; Joshua M Lang; Richard J Lee; Christopher J Logothetis; Robert Matusik; Stephen Plymate; Charles L Sawyers; Luke A Selth; Howard Soule; Wayne Tilley; Nancy L Weigel; Amina Zoubeidi; Scott M Dehm; Ganesh V Raj Journal: Eur Urol Date: 2017-12-16 Impact factor: 20.096